Biotech investor RA Capital Management LLP has registered a special purpose acquisition vehicle, Therapeutics Acquisition Corp., to raise $115 million. The SPAC is represented by Technology lawyer Jocelyn Arel of Goodwin. Read The Deal article here.
Related Content
- InsightFebruary 24, 2026
The Competition for AI’s Scarcest Resource
- InsightFebruary 17, 2026
Antitrust and Competition Technology Year in Review 2025
- AlertFebruary 12, 2026
The UK’s Ransomware Strategy: What the UK Government’s Response Signals
- InsightFebruary 2, 2026
Regulators Consider a New Theory on Algorithmic Coordination
- AlertJanuary 28, 2026
AI Risk Meets Cyber Governance:
NIST’s Draft Cyber AI Profile - AlertJanuary 15, 2026
Deadlines Approaching for Reporting 2025 ISO Exercises and ESPP Share Transfers
- AlertJanuary 14, 2026
2026 HSR Thresholds Announced: $133.9 million
- Forces of Law 2026December 10, 2025
Antitrust Authorities Rethink Coordination for the Digital Age
- EventsMarch 24, 2026
An Evening with Goodwin: AI Leaders Dinner
- Press ReleaseMarch 13, 2026
Goodwin Advises Swift Solar on Acquisition of Core Manufacturing Assets and IP From Meyer Burger
- Press ReleaseMarch 13, 2026
Goodwin Guides Tropic on $105 Million Series C
- Press ReleaseMarch 12, 2026
Goodwin Advises Underdog in Connection With Its Agreement to Acquire Aristotle Exchange DCM and Aristotle Exchange DCO
- Press ReleaseMarch 12, 2026
Goodwin Advises Legora on $550 Million Series D
- Press ReleaseMarch 12, 2026
Goodwin Advises Shellworks on $15 Million Series A Financing to Scale Sustainable Packaging Platform
- Speaking EngagementsMarch 5, 2026
Private Placements and Hybrid Securities Offerings 2026
- In the PressFebruary 26, 2026
Goodwin Hires Funds Partner Kingsbury (Financial News)